Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case

AUTOR(ES)

Gomes, Maria Antonia Ferreira, Medeiros, Lana Lira Cantidio de, Lobo, Fernanda Paula Dantas, Wanderley, Nathália Rayane Silva, Matos, Ana Paula Rodrigues, Jácome, Tácito do Nascimento, Monteiro, Maria Goretti Lins, Luz, Kleber Giovanni

FONTE

Rev. Soc. Bras. Med. Trop.

DATA DE PUBLICAÇÃO

2018-06

RESUMO

Abstract Visceral leishmaniasis is a systemic disease that is potentially severe and endemic in Brazil. It clinically manifests as fever, weight loss, swelling, hepatosplenomegaly, paleness, and edema. In this study, we discuss a case of a 1-year-old child diagnosed with refractory visceral leishmaniasis after being treated with liposomal amphotericin B in two distinct occasions. Considering the persistent clinical features and weak response to conventional treatment, a combination therapy with liposomal amphotericin B (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate was initiated, and response to treatment was good.

Documentos Relacionados

• Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil
• Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.
• Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
• Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans
• Single-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis